Human papillomavirus type 6 L1 major capsid protein (HPV6 L1) (HPV6 L1)

The Human Papillomavirus type 6 (HPV6) L1 major capsid protein is the primary structural component of the HPV6 virion, a low-risk virus responsible for approximately 90% of genital warts (condyloma acuminatum) and recurrent respiratory papillomatosis (RRP) (NIH, 2013; UniProt, 2024). This protein self-assembles into icosahedral capsids composed of 72 pentamers, which can be replicated in vitro as virus-like particles (VLPs) that are morphologically and immunologically indistinguishable from native virions (UniProt, 2024; Sino Biological, 2024). Biologically, the L1 protein mediates viral attachment by binding to heparan sulfate proteoglycans on the surface of host basal layer keratinocytes, facilitating viral entry via endocytosis (UniProt, 2024; PDBj, 2019). In pharmacology, HPV6 L1 is the central antigenic component of prophylactic vaccines like Gardasil and Gardasil 9, which induce neutralizing antibodies that block the virus's ability to attach to and enter host cells (NIH, 2013; NIH, 2022). The L1 protein also plays a critical role in encapsidating the viral double-stranded DNA genome during the assembly phase of the viral life cycle in the host cell nucleus (UniProt, 2024). While HPV6 is considered low-risk because it is rarely associated with invasive cancer, the lesions it causes can lead to significant morbidity and require repeated surgical interventions, particularly in the case of RRP (NIH, 2013). The development of L1-based VLPs has revolutionized the prevention of these conditions by providing a safe, non-infectious platform for immunization (Sino Biological, 2024).

Other names

Major capsid protein L1L1 proteinHPV6 L1 proteinLate protein L1HPV6 L1 VLP

Induction of neutralizing antibodies that bind to the L1 protein, blocking viral attachment to host cell receptors and preventing viral entry (NIH, 2013; PDBj, 2019).